Palbociclib improves survival in late endometrial cancer: study

Results from a phase 2 trial with letrozole in oestrogen receptor-positive patients presented at ESMO congress

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Palbociclib plus letrozole appears to prolong progression-free survival (PFS) in women with primary stage four or relapsed oestrogen receptor-positive endometrial cancer, Danish researchers say.

Results of the phase 2 study in 77 women were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.

Prior surgery, radiation therapy, chemotherapy or one